Cell type | Source | Receptor/neurotransmitter concentration | Costimulus | Main effect | Reference |
---|---|---|---|---|---|
Macrophage | Bone marrow, mouse | NE 10−6 M | LPS | Decrease CCR2 | [32] |
NE 10−8 M, 10−6 M | None | Decrease BMM proliferation | |||
NE 10−8 M | LPS | Increase maturation | |||
NE 10−8 M, 10−6 M | None | Increase phagocytosis | |||
NE 10−8 M, 10−6 M | LPS | Increase TNF | |||
 | Spleen, mouse | NE 10−8 M | LPS | Increase TNF | |
 | Spleen, mouse | NE 10−6 M | LPS | Decrease TNF | |
 | Peritoneum, mouse | Neuropeptide Y |  | Increase HMGB1 | [34] |
Dendritic cell | Bone marrow derived, mouse | β2-AR | NOD2 agonist | Increase IL6 | [35] |
 | TLR2 agonist | Decrease IL-12 | |||
 |  | β2-AR |  | Increase IL-33 | [36] |
 |  | α2-AR |  | Increase in antigen uptake | [37] |
 | Human cord blood | NE 10−6 M | LPS | Decrease IL12p40, TNF, IL-6, IL-23 | [38] |
T cell | Spleen, mouse | β2-AR | None | Increase Treg apoptosis | [39] |
β2-AR | Anti-CD3 | Decrease IL-2 in CD4 + CD62L+ cells | [40] | ||
β2-AR | None | Increase in Treg mediated cell suppression | |||
 | CIA, mouse | NE | ConA | Increase IFN-γ | [41] |
 | Splenic naïve T cells | β2-AR | Anti-CD3 | Decrease IL-2 | [42] |
Anti-CD28 | |||||
 |  | β2-AR | Anti-CD3 | Increase IFN-γ per Th1 cell | [43] |
Anti-CD28 | |||||
IL-12 | |||||
 | T cell clone | Neuropeptide Y | None | Decrease IFN-γ | [44] |
Increase IL-4 | |||||
B cell | CIA, mouse | β2-AR | Anti-CD40/IL-4 | Increase IL-10 | [45] |
 |  | β2-AR | Anti-CD40/IL-4 | Inhibits IL-7 receptor signaling | [46] |
 | Naïve, splenic B cells | β2-AR | CD40L/IL-4 | Increase IgG1, IgE |